Logo image of NPCE

NEUROPACE INC (NPCE) Stock Fundamental Analysis

NASDAQ:NPCE - Nasdaq - US6412881053 - Common Stock - Currency: USD

13.22  +0.11 (+0.84%)

After market: 13.22 0 (0%)

Fundamental Rating

3

Taking everything into account, NPCE scores 3 out of 10 in our fundamental rating. NPCE was compared to 188 industry peers in the Health Care Equipment & Supplies industry. NPCE has a bad profitability rating. Also its financial health evaluation is rather negative. NPCE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NPCE has reported negative net income.
NPCE had a negative operating cash flow in the past year.
In the past 5 years NPCE always reported negative net income.
NPCE had a negative operating cash flow in each of the past 5 years.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -22.51%, NPCE is in line with its industry, outperforming 47.34% of the companies in the same industry.
Looking at the Return On Equity, with a value of -102.21%, NPCE is doing worse than 62.23% of the companies in the same industry.
Industry RankSector Rank
ROA -22.51%
ROE -102.21%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

The Gross Margin of NPCE (74.83%) is better than 88.83% of its industry peers.
In the last couple of years the Gross Margin of NPCE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NPCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NPCE has been increased compared to 1 year ago.
NPCE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NPCE is higher compared to a year ago.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NPCE has an Altman-Z score of -2.71. This is a bad value and indicates that NPCE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NPCE (-2.71) is worse than 64.89% of its industry peers.
A Debt/Equity ratio of 2.46 is on the high side and indicates that NPCE has dependencies on debt financing.
NPCE has a Debt to Equity ratio of 2.46. This is amonst the worse of the industry: NPCE underperforms 86.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.46
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC8.98%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

NPCE has a Current Ratio of 6.63. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.63, NPCE belongs to the top of the industry, outperforming 85.11% of the companies in the same industry.
A Quick Ratio of 5.70 indicates that NPCE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.70, NPCE belongs to the top of the industry, outperforming 85.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.63
Quick Ratio 5.7
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.41% over the past year.
The Revenue has grown by 22.05% in the past year. This is a very strong growth!
Measured over the past years, NPCE shows a quite strong growth in Revenue. The Revenue has been growing by 16.67% on average per year.
EPS 1Y (TTM)29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.38%
Revenue 1Y (TTM)22.05%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%24.28%

3.2 Future

NPCE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.37% yearly.
Based on estimates for the next years, NPCE will show a very strong growth in Revenue. The Revenue will grow by 22.01% on average per year.
EPS Next Y15.64%
EPS Next 2Y17.88%
EPS Next 3Y18.17%
EPS Next 5Y21.37%
Revenue Next Year18.85%
Revenue Next 2Y15.62%
Revenue Next 3Y19.58%
Revenue Next 5Y22.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NPCE. In the last year negative earnings were reported.
Also next year NPCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NPCE's earnings are expected to grow with 18.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.88%
EPS Next 3Y18.17%

More info and screens

0

5. Dividend

5.1 Amount

NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROPACE INC

NASDAQ:NPCE (5/30/2025, 8:20:44 PM)

After market: 13.22 0 (0%)

13.22

+0.11 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners58.03%
Inst Owner Change37.49%
Ins Owners4.05%
Ins Owner Change-90.04%
Market Cap433.62M
Analysts84.62
Price Target17.19 (30.03%)
Short Float %1.66%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.77%
Min EPS beat(2)14.72%
Max EPS beat(2)20.82%
EPS beat(4)4
Avg EPS beat(4)20.29%
Min EPS beat(4)14.72%
Max EPS beat(4)30.58%
EPS beat(8)8
Avg EPS beat(8)21.15%
EPS beat(12)11
Avg EPS beat(12)15.63%
EPS beat(16)11
Avg EPS beat(16)6.46%
Revenue beat(2)1
Avg Revenue beat(2)0.24%
Min Revenue beat(2)-0.6%
Max Revenue beat(2)1.08%
Revenue beat(4)3
Avg Revenue beat(4)2.97%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.22%
Revenue beat(8)7
Avg Revenue beat(8)7.15%
Revenue beat(12)10
Avg Revenue beat(12)6.32%
Revenue beat(16)13
Avg Revenue beat(16)5.23%
PT rev (1m)0%
PT rev (3m)-4.07%
EPS NQ rev (1m)7.5%
EPS NQ rev (3m)11.9%
EPS NY rev (1m)8.03%
EPS NY rev (3m)12.7%
Revenue NQ rev (1m)1.55%
Revenue NQ rev (3m)1.71%
Revenue NY rev (1m)1.01%
Revenue NY rev (3m)1.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.14
P/FCF N/A
P/OCF N/A
P/B 17.87
P/tB 17.87
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.57
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.51%
ROE -102.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.83%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 2.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.93%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.63
Quick Ratio 5.7
Altman-Z -2.71
F-Score6
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)79.26%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.38%
EPS Next Y15.64%
EPS Next 2Y17.88%
EPS Next 3Y18.17%
EPS Next 5Y21.37%
Revenue 1Y (TTM)22.05%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%24.28%
Revenue Next Year18.85%
Revenue Next 2Y15.62%
Revenue Next 3Y19.58%
Revenue Next 5Y22.01%
EBIT growth 1Y26.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.52%
EBIT Next 3Y30.76%
EBIT Next 5YN/A
FCF growth 1Y49.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.11%
OCF growth 3YN/A
OCF growth 5YN/A